www.fdanews.com/articles/82225-pfizer-s-revatio-gets-european-ok-for-rare-disease
PFIZER'S REVATIO GETS EUROPEAN OK FOR RARE DISEASE
November 7, 2005
Pfizer Inc.(PFE.N: Quote, Profile, Research) said on Friday Revatio, a drug that uses the active ingredient in erectile dysfunction treatment Viagra, received European regulatory approval to treat a rare vascular disease. Pulmonary arterial hypertension, or PAH, is a blood vessel disorder of the lungs in which pressure in the pulmonary artery rises above normal levels. The condition affects about 100,000 people worldwide and is seen most commonly in women between the ages of 20 and 40.